Alvotech’s high-dose biosimilar of Humira (adalimumab) — a medication approved for ankylosing spondylitis (AS) and other inflammatory diseases — which was cleared by federal regulators earlier this year, will soon be launched in the U.S. under the brand name Simlandi. A biosimilar is a medication containing the…
Treatment with Taltz (ixekizumab) significantly eases spinal pain at night in adults with ankylosing spondylitis (AS) regardless of whether inflammation was well controlled with the therapy, according to new analyses from the Phase 3 COAST-V clinical trial. The study tested Taltz against either a placebo or adalimumab, which…
Reductions in an epigenetic marker — a type of chemical modification to DNA — called H3K27me3 were seen in people with active ankylosing spondylitis (AS) in a new study, according to researchers, who say these findings shed light on the mechanisms of the chronic inflammatory disease. The scientists believe…
Certain immune signaling molecules belonging to a family of proteins called cytokines were at altered levels in the blood of men with ankylosing spondylitis (AS) under treatment compared with men in the general population, a study found. Three cytokines with known pro-inflammatory functions — IL-17A, CXCL10, and CXCL16 —…
The gut microbiome, the collection of microbes that populate the intestinal tract, could influence the way people with inflammatory bowel disease (IBD) and associated peripheral spondyloarthritis (SpA) respond to sulfasalazine — a medication commonly used to treat IBD that’s also been shown to be effective for SpA. That’s according to…
People with inflammatory bowel disease (IBD) are at significantly higher risk for various forms of spondyloarthritis (SpA), including ankylosing spondylitis (AS), a study found. But the reverse wasn’t true: Having SpA was not linked to an increased risk of developing IBD, according to the new analysis, which used genetic…
The responses to Cosentyx (secukinumab) among people with ankylosing spondylitis (AS) and other inflammatory diseases aren’t significantly impacted by a person’s genetic background, a recent study suggests. The findings challenge an existing hypothesis that the variable responses to the therapy in clinical practice could largely be driven by…
Exosomes, which are tiny carriers for cellular cargo, are found to have significantly different contents in ankylosing spondylitis (AS) patients compared with healthy people, which in turn has marked influences on immune cell function, according to a recent study. Researchers specifically identified that the profile of molecules called microRNAs…
The effects of inflammation on the later development of new bone outgrowths in certain parts of the spine in ankylosing spondylitis (AS) patients are largely not explained by the intermediate formation of fatty deposits, according to a new study. The findings, which take into account data from two clinical…
Xeljanz (tofacitinib) treatment led to significant reductions in spinal inflammation in people with ankylosing spondylitis (AS), according to analyses from a Phase 2 trial. Reductions were seen in the posterolateral spine and facet joints, which are commonly affected in AS and represent important treatment targets, but are often…
Get regular updates to your inbox.